Nuvilex, Inc. Moves Closer to "Bio-Artificial Pancreas" Diabetes Treatment With License for Insulin-Producing Cells
21. Oktober 2014 09:00 ET
|
Nuvilex, Inc.
NEW YORK, NY--(Marketwired - October 21, 2014) - Nuvilex, Inc. (OTCQB: NVLX) has carefully mapped out its plan to develop a diabetes treatment using the Cell-in-a-Box®
platform technology. It started...
Nuvilex's Cancer Treatment Obtaining FDA Orphan Drug Status Would Make Company Attractive Big Pharma Target
14. Oktober 2014 09:00 ET
|
Nuvilex, Inc.
NEW YORK, NY--(Marketwired - October 14, 2014) - Nuvilex, Inc. (OTCQB: NVLX) has officially introduced its advanced pancreatic cancer treatment to the U.S. Food and Drug Administration (FDA) in an...
Nuvilex Eyeing Partnership for Its Share of Future $114 Billion Diabetes Market
07. Juli 2014 09:00 ET
|
Nuvilex, Inc.
NEW YORK, NY--(Marketwired - Jul 7, 2014) - Nuvilex, Inc. (OTCQB: NVLX) announced last week that its executives recently met with the company's "global development partners" at the 2014 BIO...
Nuvilex Inc., TD2 and the PCRT Should Draw Great Interest to the Company's Pancreatic Cancer Treatment
20. Juni 2014 09:00 ET
|
Nuvilex, Inc.
NEW YORK, NY--(Marketwired - Jun 20, 2014) - Nuvilex, Inc. (OTCQB: NVLX) can accomplish more in its upcoming preclinical trials than many may realize. With the announcement that Translational...
Nuvilex Heads to the Clinic With an Opportunity to Treat a Wider Range of Cancers
12. Juni 2014 09:00 ET
|
Nuvilex, Inc.
NEW YORK, NY--(Marketwired - Jun 12, 2014) - Nuvilex, Inc. (OTCQB: NVLX) and its shareholders should soon experience an event that, to date, has not been enjoyed by the Maryland biotech...
Nuvilex CEO and COO Discuss Preclinical and Clinical Trials, Orphan Drug Status, Funding and Much More in Interview
04. Juni 2014 08:30 ET
|
Nuvilex, Inc.
NEW YORK, NY--(Marketwired - Jun 4, 2014) - Nuvilex, Inc. (OTCQB: NVLX) President and CEO Kenneth Waggoner and COO Dr. Gerald Crabtree addressed a number of topics associated with the company's...
Nuvilex Now Has Access to $50 Million With New Banking Agreement
02. Juni 2014 09:00 ET
|
Nuvilex, Inc.
NEW YORK, NY--(Marketwired - Jun 2, 2014) - Nuvilex (OTCQB: NVLX) has become quite a busy biotechnology firm of late, and with the announcement of what is now a "two-pronged attack" on pancreatic...
Nuvilex CEO and COO to Sit for Recorded Interview at 50th Annual ASCO Conference This Weekend
28. Mai 2014 09:00 ET
|
Nuvilex, Inc.
NEW YORK, NY--(Marketwired - May 28, 2014) - After traveling all over the globe for the better part of the last two months putting the pieces in place for its two-pronged attack on pancreatic...
Nuvilex Eyes FDA Accelerated Approval Process by Improving Quality of Life in Pancreatic Cancer Patients
23. Mai 2014 09:00 ET
|
Nuvilex, Inc.
NEW YORK, NY--(Marketwired - May 23, 2014) - Nuvilex (OTCQB: NVLX) is calling it a "two pronged attack" on pancreatic cancer, but investors may be calling it an "end-around" or another avenue of...
Nuvilex Positioned for Lucrative Deal With Cell-in-a-Box Technology's Diverse Treatments Amid Biotech Frenzy
20. Mai 2014 09:00 ET
|
Nuvilex, Inc.
NEW YORK, NY--(Marketwired - May 20, 2014) - Nuvilex, Inc. (OTCQB: NVLX) is up to much more than most are currently aware of, and it only takes a bit of digging to realize it. The company is clearly...